Story no.231OngoingHealthNotableCôte-d'Or +128 Oct → 11 Nov18 facts · 75 art.
Anti-obesity GLP-1 in France: reimbursement, diverted uses and health alerts
In early November 2026, the testimony of a patient treated with Mounjaro and the limits of reimbursement for anti-obesity treatments in Dijon open the file, while a survey indicates that one in five French people would be willing to use GLP-1s to lose weight. The appetite suppressant market is growing strongly and adverse effects are multiplying, with customs stepping up controls against trafficking of products such as Wegovy. The health risks of Ozempic and Wegovy are highlighted, and the €100 million envelope for reimbursement is deemed insufficient. Influencers are accused of diverting these medicines, patients are turning to parallel markets, and a former obese person warns about Wegovy. Health professionals sound the alarm on weight-loss injections, then a Lilly France campaign against fatphobia is suspected of being disguised advertising for Mounjaro.
In brief
Ongoing story bringing together 18 events nationwide, followed from 28 October 2026 to 11 November 2026. 75 articles from 23 sources (health); last updated on 11 November 2026 at 07:00.
62 articles of rated outlets · 13 unrated outside the bar · 23 sources (75 art.) · the three sides talk about it · outlets: left 5, centre 15, right 2
Angle comparison for the whole story
All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center develops waiting times, the parallel market and patient testimonies, while the right highlights the non-reimbursable nature and practical information (price, side effects).
Left
Highlights the rivalry between Novo Nordisk and Eli Lilly on a fast-growing global market, as well as the lack of reimbursement for pills and side effects to be aware of.
Centre
Develops concrete consequences: waiting times of up to 18 months, parallel market, position of drug treatments compared with bariatric surgery and patient testimonies.
Right
Emphasizes the non-reimbursable nature of oral Wegovy and offers a practical format listing price, side effects and reimbursement.
Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41
Confirmed by several sources(5)
- 7
Wegovy tablets are marketed in France from November 2.
7 independent sourcesBFMTV / RMC, Paris-Normandie, Midi Libre, 20 Minutes, La Dépêche du Midi +4
- 5
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
5 independent sourcesMidi Libre, Le Moniteur des pharmacies, 20 Minutes, Libération, Les Échos
- 2
Waiting times in specialized consultations authorized to prescribe anti-obesity medications reach up to 18 months.
2 independent sourcesLes Échos, Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain
- 2
Oral Wegovy contains semaglutide, a GLP-1 receptor agonist.
2 independent sourcesParis-Normandie, TF1 Info / LCI
- 2
Injectable Wegovy has been available in France since 2024 and has been reimbursed under conditions since June 2026.
2 independent sourcesLe Progrès, TF1 Info / LCI
Single source so far(5)
- The European Commission authorized oral Wegovy on July 15, 2026. (according to Paris-Normandie)
- A parallel market for these medicines is thriving, difficult to quantify. (according to Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain)
- Professor Emmanuel Disse said: “The more patients are treated, the more there will be bariatric surgery.” (according to Le Progrès, Le Bien Public, L'Est Républicain)
- Meta Tshiteya, treated with Mounjaro for three years, has lost 50 kg. (according to L'Est Républicain, Le Dauphiné libéré, Le Progrès)
AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41
Checked on the web(3)
- Not confirmed at this stage
Wegovy tablets are marketed in France from November 2.
Sources: ansm.sante.fr(official), www2.assemblee-nationale.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr
1 Nov, 22h44
- Not confirmed at this stage
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
Sources: ansm.sante.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr, prescrire.org
1 Nov, 22h44
- Not confirmed at this stage
The European Commission authorized oral Wegovy on July 15, 2026.
Sources: lagazettefrance.fr, prescrire.org, ameli.fr, qare.fr, 20minutes.fr
1 Nov, 22h44
Automatic web search, official sources first · “contradicted” only when an official source is cited
Timeline
newest firstOutlets:LeftCentreRightUncategorised· badge = severity
In figures
Further reading
People cited
Organisations cited
Places cited
Go up the thread
Events in the story
- Près d'un Français sur cinq prêt à prendre des anti-obésité GLP-1 pour maigrir11 Nov
- Une campagne anti-grossophobie de Lilly France soupçonnée de publicité déguisée pour le Mounjaro10 Nov
- Les risques sanitaires des traitements anti-obésité Ozempic et Wegovy9 Nov
- Alerte des professionnels de santé sur des piqûres pour maigrir9 Nov
- Un ancien obèse alerte sur l'effet « dévastateur » du Wegovy sur M68 Nov
- Wegovy tablet arrives in French pharmacies8 Nov
- Un nutritionniste fait le point sur les médicaments anti-obésité8 Nov
- Des Français prêts à contourner les prescriptions pour accéder aux anti-obésité8 Nov
- Des influenceuses détournent les médicaments anti-obésité pour vanter leur minceur8 Nov
- Remboursement de l'obésité : l'enveloppe de 100 millions jugée insuffisante7 Nov
Affected departments